You are here

1 PI


This is a generic educational information sheet for 1 PI regimens.

Efficacy in clinical trials:

Trial Name Drugs Compared Participants Results
  PI Monotherapy 528 tx   experienced Of the 529 patients virologically suppressed who switched to a boosted protease inhibitor monotherapy individuals with less than 1 year of prior sustained virological suppression were more likely to experience virological failure on boosted protease inhibitor monotherapy (BPIMT) for a duration of 12-23 months and 24 months or more. Rates of failure were similar for BPIMT with lopinavir-ritonavir or darunavir-ritonavir, but increased for BPIMT with atazanavir-RTV [1]
  Dual ARV w/ PI 131 tx experienced

131 HIV-1 infected patients who switched to a maintenance dual antiretroviral regimen containing a boosted PI were followed for a median of 14 months. Virological failure rate was 90.1%. Two patients had virological failure and 11 discontinued treatment due to side effects or were lost to follow-up [2].




  1. Citekey 198 not found
  2. Citekey 199 not found